Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

Blood - 15 Sept 2002

Neben Kai, Mytilineos Joannis, Moehler Thomas M, Preiss Astrid, Kraemer Alwin, Ho Anthony D, Opelz Gerhard, Goldschmidt Hartmut

Abstract excerpt

Thalidomide (Thal) is a drug with antiangiogenic, anti-inflammatory, and immunomodulatory properties that was found to inhibit the production of tumor necrosis factor-alpha (TNF-alpha) in vitro. We studied single nucleotide polymorphisms at positions -308 and -238 of the TNF-alpha gene promoter a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Haplotypes
Share to Multiple Myeloma
Share to Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Promoter Regions, Genetic

Share to Salvage Therapy

Share to Survival Analysis

Share to Thalidomide

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 12200397

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12200397-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.PMID 12200397Read ↗

[Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma].Semantic proximity Read ↗

Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.Semantic proximity Read ↗

Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Effect of Cytokine Genes in the Pathogenesis and on the Clinical Parameters for the Treatment of Multiple Myeloma.Semantic proximity Read ↗

Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis.Semantic proximity Read ↗

Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients.Semantic proximity Read ↗

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.Semantic proximity Read ↗

Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.Semantic proximity Read ↗

The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple MyelomaSemantic proximity Read ↗

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.Semantic proximity Read ↗

Role of Genetic Polymorphisms -238 G>A and -308 G>A, and Serum TNF-α Levels in a Cohort of Mexican Pediatric Neuroblastoma Patients: Preliminary Study.Semantic proximity Read ↗

Interleukin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.